Risk factors for piperacillin/tazobactam resistance in extended-spectrum beta-lactamase (ESBL) producing organisms

Next Previous
Trial Profile

Risk factors for piperacillin/tazobactam resistance in extended-spectrum beta-lactamase (ESBL) producing organisms

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Piperacillin/tazobactam (Primary)
  • Indications Enterobacteriaceae infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2025.
    • 09 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2025.
    • 09 Jun 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top